ClinicalTrials.gg
CompletedNCT00716391Updated May 24, 2019

TPF Plus Cisplatin and Radiotherapy vs TPF Plus Cetuximab and Radiotherapy to Treat Head and Neck Cancer.

A Phase 3 interventional study of TPF, radiotherapy and cisplatin. and TPF, radiotherapy and cetuximab. in Head and Neck Cancer, sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello. Completed at 39 sites in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-05-24.

Sponsored by Grupo Español de Tratamiento de Tumores de Cabeza y Cuello · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
519
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Head and Neck Neoplasms with a site in Spain — 16 open to participants now, 35 under way, 7 of them phase 3. Head and Neck Neoplasms · Spain.

Enrollment
19th of 123
519 · median 141
Started
2008
with 1 other
Phase 3
26 of 128
1 open now
Registered
20th of 128
by date
Lead sponsor
4 of 128
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

Among the 128 studies in Head and Neck Neoplasms with a site in Spain, this one is the 19th largest by enrollment of the 123 interventional ones that give a count, is one of 2 that started in 2008, is one of 26 in phase 3, and was the 20th registered.

Head and Neck Neoplasms

2,718 studies on the registry are indexed under Head and Neck Neoplasms; 599 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

16 of the 128 studies in Head and Neck Neoplasms with a site in Spain are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 458 Head and Neck Neoplasms studies recruiting now, 350 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Head and Neck Neoplasms with a site in Spain, or all of them as a file.
02

Study summary

An Open Label Randomized, Multi-Centre Phase III Trial of TPF Chemotherapy Plus Concomitant Treatment With Cisplatin and Conventional Radiotherapy Versus TPF Chemotherapy Plus Concomitant Cetuximab and Conventional Radiotherapy in Locally Advanced, Unresectable Head and Neck Cancer.

Read the detailed description

This study is being sponsored by a cooperative medical group.

03

Conditions studied

  • Head and Neck Cancer

Keywords

  • Head and Neck Cancer
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Before the beginning of protocol's specific procedures, the has to be obtained.
  2. Locally advanced cancer of head and neck (oral cavity, oropharynx, larynx and hypopharynx) stage III-IV, without evidence of .
  3. The tumor must be considered to be non-operable according to the criteria of the Northern California Oncology Group. The reason of non-surgical resection will be annotated in the CRF.

    Criteria of non-surgical resection according to the NCOG:

    3.1.Technically not resectable (includes: evidence of mediastinal dissemination; fixed tumor to the clavicle, base of the cranium or cervical vertebrae; affectation of the nasopharynx).

    3.2.Medical criteria based on a low surgical curability. 3.3.Medical for the surgery.

  4. Epidermoid carcinoma histologically demonstrated
  5. according to the criteria .
  6. Men or women with age between 18 and 70 years, both inclusive.
  7. Functional condition index according to scale:0-1
  8. Patients in medical conditions to be able to receive treatment with TPF induction followed by normofractionated radiotherapy with cetuximab or cisplatin.
  9. Patients with adequate hematologic function: neutrophils superior or equal to 2 x 109, superior or equal to 100 x 109, superior or equal to 10 g/dl.
  10. Adequate hepatic function: lower or equal to 1 x top normal Limit, GOT and GPT lower or equal to 2,5 Top Normal Limit , alkaline phosphatase \< 5 Top Normal Limit.
  11. Adequate renal function: creatinin \<1,4 mg/dl (120 µmol/l); if the values are > 1,4 mg/dl, the clearance of creatinin will have to be > 60 ml/min (real or calculated for 's method).
  12. Calcium lower or equal to 1,25 x top normal limit.
  13. Adequate nutritional condition: loss of weight \<20% with relation to the theoretical weight and albumin superior or equal to 35 g/L.
  14. Patients must be accessible for the treatment and the follow-up.

Exclusion criteria

Exclusion Criteria:

  1. disease
  2. Surgical treatment, previous radiotherapy and/or chemotherapy for the study disease.
  3. Other tumor locations in head and neck that are not oral cavity, oropharynx, larynx, hypopharynx.
  4. Other stages that are not III or IVM0.
  5. Other previous and / or synchronic squamous carcinoma.
  6. Diagnosis of another neoplasia in the last 5 years, excepting carcinoma in situ of uterine neck and/or a cutaneous carcinoma basocellular properly treated.
  7. Active infection(at needs endovenous antibiotics), including active tuberculosis and diagnosed .
  8. Not controlled hypertension defined as arterial systolic tension superior or equal to 180 mm Hg and / or diastolic arterial tension superior or equal to 130 mm Hg baseline.
  9. Pregnancy(absence must be confirmed with the test of beta-HCG) or period of lactation.
  10. Immunity systemic treatment, chronic and concomitant, or hormonal treatment of the cancer.
  11. Other antineoplastic concomitant treatments.
  12. Coronary arteriopathy or precedents of myocardial infarction in the last 12 months or high risk of not controlled arrhythmia or cardiac not controlled insufficiency.
  13. Pulmonary obstructive chronic disease that had needed 3 or more hospitalizations in the last 12 months.
  14. Active non controlled peptic ulcer.
  15. Presence of a psychological or medical disease that could prevent to accomplish the study by the patient or to grant his/her signature in the form.
  16. Known drugs abuse (with the exception of excessive consumption of alcohol)
  17. Known allergic reaction to some of the components of the treatment of the study.
  18. Previous treatment with monoclonal antibodies or other transduction of the sign inhibitors or treatment directed against the EGFR.
  19. Any experimental treatment in 30 days before the entry in the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
519 participants (actual)

Study arms

  • Active comparator
    Group A

    TPF plus concomitant treatment with cisplatin and conventional radiotherapy.

    Other: TPF, radiotherapy and cisplatin.

  • Experimental
    Group B

    TPF plus concomitant treatment with cetuximab and conventional radiotherapy

    Other: TPF, radiotherapy and cetuximab.

Interventions

  • OtherTPF, radiotherapy and cisplatin.

    3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days

    Also known as: TPF plus radiotherapy and cisplatin

  • OtherTPF, radiotherapy and cetuximab.

    3 cycles of: cisplatin: 75 mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracil: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy, divided into daily doses of 2 Gray (total days: 35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days

    Also known as: TPF plus radiotherapy and cetuximab

06

What researchers measure

Primary outcomes

  1. Global survival

    The time from the start of induction chemotherapy with TPF to death due to any cause or to the last check-up in the case of living patients

    Time frame: Up to 89 months

Secondary outcomes

  1. Overall response rate (ORR)

    The response rate (CR + PR) measured using the RECIST 1.0 method.

    Time frame: Up to 89 months

  2. Progression free-survival (PFS)

    Time to progression as the time since the start date of treatment with TPF induction chemotherapy until the time when DP occurred or death occurred due to any cause.

    Time frame: Up to 89 months

  3. Time to loco-regional control of disease

    As permanent and complete resolution of the disease in terms of its initial site and lymph nodes (T and N). If the disease lasted (regardless of size), the tumor recurred, or a second tumor appeared in the field RT, it will be recorded as a therapeutic failure.

    Time frame: Up to 89 months

  4. Satisfaction with treatment. Analysis of QoL in both treatment arms.

    EORTC QoL questionnaires: C30 version 3.0 and QLQ-H\&N35 module

    Time frame: Up to 89 months

07

Study locations

39 sites
  • Hospital Puerta del Mar
    Almeria, Almería, Spain
  • Hospital Germans Trias i Pujol
    Badalona, Barcelona 08916, Spain
  • Hospital Durán i Reynals
    Hospitalet de Ll., Barcelona, Spain
  • Hospital de Manresa
    Manresa, Barcelona, Spain
  • Hospital Mútua de Terrassa
    Terrassa, Barcelona, Spain
  • Hospital Son Dureta
    Palma de Mallorca, Mallorca 07014, Spain
  • Hospital Son Llàtzer
    Palma De Mallorca, Mallorca 07198, Spain
  • Hospital de Sagunto
    Sagunto, Valencia, Spain
  • Hospital general Universitario
    Alicante, Spain
  • Hospital Clínic i Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital de Basurto
    Bilbao, Spain
  • Hospital General Yagüe
    Burgos, Spain
  • Hospital San Pedro de Alcántara
    Cáceres, Spain
  • Hospital Dr. Trueta (ICO Girona)
    Girona, 17007, Spain
  • Oncogranada
    Granada, 18014, Spain
  • H. Virgen de las Nieves
    Granada, Spain
  • Hospital General de Jaén
    Jaén, Spain
  • Hospital Xeral Calde
    Lugo, Spain
  • Hospital Universitari Arnau de Vilanova
    Lérida, 25198, Spain
  • Hospital Clínico San Carlos
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Clínica Quirón
    Madrid, Spain
  • Fundación Jiménez Díaz
    Madrid, Spain
  • Hospital Gregorio Marañon
    Madrid, Spain
  • Hospital La Paz
    Madrid, Spain
  • Hospital Universitario Central de Asturias
    Oviedo, 33006, Spain
  • Hospital Universitario de Salamanca
    Salamanca, 37007, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Clínico de Santiago
    Santiago de Compostela, Spain
  • Hospital General de Segovia
    Segovia, Spain
  • Hospital Arnau de Vilanova
    Valencia, 46015, Spain
  • Hospital General Universitario
    Valencia, Spain
  • Hospital La Fe
    Valencia, Spain
  • Hospital Xeral Cies
    Vigo, 36024, Spain
  • Hospital de Meixoeiro
    Vigo, 36200, Spain
  • Hospital Provincial de Zamora
    Zamora, 49021, Spain
  • Hospital Clínico Lozano Blesa
    Zaragoza, Spain
  • Hospital Miguel Servet
    Zaragoza, Spain
  • Hospital Nuestra Señora de Sonsoles
    Ávila, Spain
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2008 to primary completion in Jul 2017, 108 months.

Of 48 non-industry phase 3 interventional studies under Head and Neck Neoplasms, half reached primary completion within 76 months of starting (the median), counting those still running; a quarter within 53 and three quarters within 108. This study's 108 months is above that.

Counting every sponsor, half of 66 studies reached it within 61 months; a quarter within 34 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 14, 2008
First posted
Jul 16, 2008
StartActual
Jul 7, 2008
Primary completionActual
Jul 18, 2017
CompletionActual
Dec 2017
Last update
May 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00716391
Lead sponsor
Grupo Español de Tratamiento de Tumores de Cabeza y Cuello
Responsible party
Sponsor
First posted
Jul 16, 2008
Start date
Jul 7, 2008
Primary completion
Jul 18, 2017
Completion
Dec 2017
Last update
May 24, 2019

Study contacts

Juan J Cruz, Professor
principal investigator · University of Salamanca
Ricardo Hitt, MD
principal investigator · Hospital Universitario 12 de Octubre

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion